London, UK – [10.09.24] – PHARMExcel, a leading Contract Research Organisation (CRO) headquartered in the UK, is thrilled to announce its nomination as a finalist for the prestigious “Most Impactful CRO of the Year” award at the OBN Awards 2024. This recognition underscores PHARMExcel’s unwavering commitment to advancing clinical research, particularly in areas with significant unmet patient needs, such as ophthalmology and rare disease.
The OBN Awards, renowned for celebrating innovation and excellence across the life sciences sector, have shortlisted PHARMExcel in recognition of the company’s outstanding contributions to clinical trial management. PHARMExcel’s nomination is a testament to its dedication to driving impactful research outcomes, fostering strong client relationships, and ensuring the integrity and efficiency of the clinical trial process.
One area PHARMExcel has made a substantial impact is rare disease, with a focus ophthalmology, where there is a critical need for innovative treatments. Through its long-standing partnership with Moorfields Eye Hospital and other world-leading ophthalmic centres across the UK, it has enabled the escalation of research that has the potential to transform the lives of thousands of patients with rare vision impairments and other ophthalmic conditions. The company’s expertise in managing complex ophthalmology studies ensures that these trials are conducted with precision, leading to reliable data and, ultimately, breakthroughs that can bring much-needed treatments to market.
We are honoured to be recognised as a finalist for the Most Impactful CRO of the Year at the OBN Awards 2024,” said Yvanne Enever, CEO of PHARMExcel. “This nomination reflects the hard work and dedication of our entire team, particularly in areas of rare disease where our work can make a real difference in addressing unmet patient needs. We are passionate about delivering excellence in every aspect of our work, and this recognition further motivates us to continue setting new benchmarks in the industry.
"PHARMExcel’s passion for its clinical trials, the professionalism and expertise demonstrated, combined with direct access to the CEO, Yvanne Enever, sets PHARMExcel apart from other CROs". "
Quote from Sponsor
The winners of the OBN Awards 2024 will be announced at a ceremony in London later this year. Regardless of the outcome, PHARMExcel remains committed to making a lasting impact on the clinical research industry and improving patient outcomes, particularly in areas where new therapies are most needed.
PHARMExcel is an award-winning, full-service Contract Research Organisation (CRO) that genuinely delivers a flexible and innovative approach to clinical trial delivery. The company is recognised for its in-depth knowledge and experience of the clinical research environment, particularly in the UK, and has a network of regulatory and industry associates, allowing it to provide a global reach.
Tel: +44 (0) 2036426654
Email: [email protected]
